These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 15288287)
41. Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer. Altundag K; Altundag O; Gunduz M Breast Cancer Res Treat; 2005 Jan; 89(2):213. PubMed ID: 15692765 [No Abstract] [Full Text] [Related]
42. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955 [TBL] [Abstract][Full Text] [Related]
43. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases. El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812 [TBL] [Abstract][Full Text] [Related]
44. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature. Abudu EK; Musa O; Adefuye PO; Abdul Kareem FB; Agboola AO; Banjo AA Niger Postgrad Med J; 2007 Dec; 14(4):355-7. PubMed ID: 18163149 [TBL] [Abstract][Full Text] [Related]
45. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210 [TBL] [Abstract][Full Text] [Related]
46. [The use of GnRH analogues in early and advanced breast carcinomas]. Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613 [TBL] [Abstract][Full Text] [Related]
47. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
48. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Hughes LL; Gray RJ; Solin LJ; Robert NJ; Martino S; Tripathy D; Ingle JN; Wood WC; ; ; ; Cancer; 2004 Sep; 101(5):969-72. PubMed ID: 15329905 [TBL] [Abstract][Full Text] [Related]
49. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Hubalek M; Ramoni A; Mueller-Holzner E; Marth C Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144 [TBL] [Abstract][Full Text] [Related]
50. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group]. Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641 [TBL] [Abstract][Full Text] [Related]
51. Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice. Sacco SM; Power KA; Chen J; Ward WE; Thompson LU Exp Biol Med (Maywood); 2007 Jun; 232(6):754-61. PubMed ID: 17526767 [TBL] [Abstract][Full Text] [Related]
52. Endometrial cancer within tamoxifen-related polyps in patients with breast cancer. Tate S; Yamazawa K; Sekiya S Acta Obstet Gynecol Scand; 2004 Aug; 83(8):769-70. PubMed ID: 15255851 [No Abstract] [Full Text] [Related]
53. Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer. Sakurai K; Matsuo S; Enomoto K; Amano S; Shiono M Surg Today; 2011 Jan; 41(1):48-53. PubMed ID: 21191690 [TBL] [Abstract][Full Text] [Related]
55. Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer. Matsumoto M; Miyauchi M; Yamamoto N; Shishikura T; Imanaka N Breast Cancer; 2000; 7(3):237-40. PubMed ID: 11029804 [TBL] [Abstract][Full Text] [Related]
56. [Gonadotropin-releasing hormone analogues in the treatment of metastatic breast carcinoma]. Nesković-Konstantinović Z; Radulović S; Vuletić L Srp Arh Celok Lek; 1993; 121(1-2):33-5. PubMed ID: 8202820 [TBL] [Abstract][Full Text] [Related]
57. Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density. Altundag K Breast Cancer; 2024 Sep; 31(5):997. PubMed ID: 38762702 [No Abstract] [Full Text] [Related]
58. Successful management of an ovarian enlargement resembling ovarian hyperstimulation in a premenopausal breast cancer patient receiving tamoxifen with cotreatment of GnRH-agonist. Turan C; Unal O; Dansuk R; Guzelmeric K; Cengizoglu B; Esim E Eur J Obstet Gynecol Reprod Biol; 2001 Jul; 97(1):105-7. PubMed ID: 11435021 [TBL] [Abstract][Full Text] [Related]
59. [Tamoxifen in breast cancer: viewpoint of the gynecologist]. De Muylder X Acta Clin Belg; 1992; 47(3):178-84. PubMed ID: 1332348 [TBL] [Abstract][Full Text] [Related]
60. [Effectiveness of skin icing for reducing pain associated with luteinizing hormone-releasing hormone agonist injection]. Nomura T; Tsunoda K; Ohta S; Doi K; Miyoshi K; Hasegawa Y; Mizutani M Gan To Kagaku Ryoho; 2014 Feb; 41(2):221-4. PubMed ID: 24743201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]